Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients

A receiver operating curve analysis was performed to assess the predictive value of the urinary cystatin C to urinary creatinine ratio for the renal monitoring of tenofovir. Urinary cystatin C to urinary creatinine ratio was measured in 37 samples from patients referred for suspected tenofovir-induced Fanconi syndrome. The best threshold (14 μg/mmol) was associated with sensitivity, 90.9%; specificity, 88.5%; positive predictive value, 76.9%; and negative predictive value, 95.8%. Urinary cystatin C to urinary creatinine ratio allows to rule out a Fanconi syndrome in most cases; thus, it should be used for the safety follow-up of nucleotide reverse transcriptase inhibitor-treated patients.

[1]  B. Clotet,et al.  Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. , 2009, Blood.

[2]  F. Tacke,et al.  Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. , 2008, The Journal of infectious diseases.

[3]  V. Soriano,et al.  Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. , 2008, AIDS.

[4]  C. Mazzucco,et al.  Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance , 2008, Hepatology.

[5]  C. Torti,et al.  Evidence of Long-Term Suppression of Hepatitis B virus DNA by Tenofovir as Rescue Treatment in Patients Coinfected by HIV , 2008, Antiviral therapy.

[6]  S. Mauss,et al.  Treatment of chronic hepatitis B and the implications of viral resistance to therapy , 2008, Expert review of anti-infective therapy.

[7]  H. Schuitemaker,et al.  A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. , 2008, The Journal of infectious diseases.

[8]  S. Weissman,et al.  Prevalence of Chronic Kidney Disease in an Urban HIV Infected Population , 2008, The American journal of the medical sciences.

[9]  B. Clotet,et al.  HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro , 2008, AIDS.

[10]  J. Nazroo,et al.  Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK , 2008, AIDS.

[11]  J. Parry,et al.  Sexual behaviour and HIV infection in black-Africans in England: results from the Mayisha II survey of sexual attitudes and lifestyles , 2007, Sexually Transmitted Infections.

[12]  Amalio Telenti,et al.  HIV entry inhibitors , 2007, The Lancet.

[13]  B. Walker,et al.  Effective T-Cell Responses Select Human Immunodeficiency Virus Mutants and Slow Disease Progression , 2007, Journal of Virology.

[14]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[15]  T. Luedde,et al.  Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  S. Tett,et al.  Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis. , 2007, Clinical biochemistry.

[17]  D. Clifford,et al.  Frequency and Phenotype of JC Virus-Specific CD8+ T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy , 2007, Journal of Virology.

[18]  C. Sabin,et al.  The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004) , 2006, AIDS.

[19]  Todd M. Allen,et al.  HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1 , 2006, PLoS medicine.

[20]  Todd M. Allen,et al.  Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. , 2006, The Journal of infectious diseases.

[21]  Lei Wang,et al.  A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. , 2006, The Journal of infectious diseases.

[22]  G. Marks,et al.  Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA , 2006, AIDS.

[23]  S. Tezenas du Montcel,et al.  Changing Electrolyte and Acido-Basic Profile in HIV-Infected Patients in the HAART Era , 2006, Nephron Physiology.

[24]  F. Mitjans,et al.  Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. , 2006, Antiviral research.

[25]  D. Douek,et al.  HIV disease: fallout from a mucosal catastrophe? , 2006, Nature Immunology.

[26]  Mark Marsh,et al.  Virus Entry: Open Sesame , 2006, Cell.

[27]  G. Braden,et al.  Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  B. Autran,et al.  Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. , 2005, The Journal of infectious diseases.

[29]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[30]  Philip J. R. Goulder,et al.  HIV-1 Viral Escape in Infancy Followed by Emergence of a Variant-Specific CTL Response1 , 2005, The Journal of Immunology.

[31]  M. Manns,et al.  CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter , 2005, Gut.

[32]  S. Dougan,et al.  HIV infections acquired through heterosexual intercourse in the United Kingdom: findings from national surveillance , 2005, BMJ : British Medical Journal.

[33]  E. Rosenberg,et al.  Limited Durability of Viral Control following Treated Acute HIV Infection , 2004, PLoS medicine.

[34]  M. Manns,et al.  Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies. , 2004, Current medicinal chemistry.

[35]  T. Luedde,et al.  Basal Core Promoter and Precore Mutations in the Hepatitis B Virus Genome Enhance Replication Efficacy of Lamivudine-Resistant Mutants , 2004, Journal of Virology.

[36]  Alessandro Sette,et al.  Selection, Transmission, and Reversion of an Antigen-Processing Cytotoxic T-Lymphocyte Escape Mutation in Human Immunodeficiency Virus Type 1 Infection , 2004, Journal of Virology.

[37]  E. Rosenberg,et al.  Primary HIV type 1 infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  D. Shoback,et al.  Fanconi's Syndrome in HIV+ Adults: Report of Three Cases and Literature Review , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  J. Hulot,et al.  Renal safety of tenofovir in HIV treatment-experienced patients , 2004, AIDS.

[40]  A. Kribben,et al.  Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. , 2004, Clinical chemistry.

[41]  Todd M. Allen,et al.  Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection , 2003, AIDS (London).

[42]  Stephen J O'Brien,et al.  The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.

[43]  B. Evans,et al.  Impact of the HIV epidemic in sub-Saharan Africa on the pattern of HIV in the UK , 2003, AIDS.

[44]  F. Zoulim,et al.  Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants , 2003, Journal of Virology.

[45]  H. Isom,et al.  Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine‐resistant HBV in vitro , 2003, Hepatology.

[46]  Todd M. Allen,et al.  HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus , 2002, Nature.

[47]  S. Hasnain,et al.  Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus , 2002, Journal of medical virology.

[48]  A. Gotoh,et al.  Measurement of cystatin-C and creatinine in urine. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[49]  C. Gibbs,et al.  Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.

[50]  J. Lepkowski,et al.  American Adolescents: Sexual Mixing Patterns, Bridge Partners, and Concurrency , 2002, Sexually transmitted diseases.

[51]  A. Copas,et al.  Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. , 2001, AIDS.

[52]  J. Lisziewicz,et al.  Control of SIV rebound through structured treatment interruptions during early infection. , 2000, Science.

[53]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[54]  W. Ryu,et al.  Evidence that the 5′-End Cap Structure Is Essential for Encapsidation of Hepatitis B Virus Pregenomic RNA , 2000, Journal of Virology.

[55]  F. Zoulim,et al.  Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. , 2000, The Journal of infectious diseases.

[56]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[57]  J. Lisziewicz,et al.  Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. , 1999, The Journal of infectious diseases.

[58]  J. Lisziewicz,et al.  Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.

[59]  J. Goedert,et al.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.

[60]  B. Walker,et al.  Acute human immunodeficiency virus type 1 infection. , 1998, The New England journal of medicine.

[61]  J. Phair,et al.  A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation , 1998, Nature Medicine.

[62]  G. Daker-White,et al.  Assortative sexual mixing in a heterosexual clinic population ‐ a limiting factor in HIV spread? , 1997, AIDS.

[63]  J. Beijnen,et al.  Clinically relevant drug interactions with antiretroviral agents. , 1997, Antiviral therapy.

[64]  P. Klenerman,et al.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  F. Chisari,et al.  The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice , 1996, Journal of virology.

[66]  Glen A. Satten,et al.  Markov Chains with Measurement Error: Estimating the ‘True’ Course of a Marker of the Progression of Human Immunodeficiency Virus Disease , 1996 .

[67]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[68]  J. Goedert,et al.  Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection , 1996, Nature Medicine.

[69]  D. Hawkins,et al.  A controlled trial of zidovudine in primary human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[70]  J. Berger.  Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: Explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions , 2011, Journal of NeuroVirology.

[71]  A. Durrbach,et al.  Urinary cystatin C as a specific marker of tubular dysfunction , 2006, Clinical chemistry and laboratory medicine.

[72]  David Y. Huang,et al.  Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. , 2005, Nature medicine.

[73]  Mardge H. Cohen,et al.  Predictors of proteinuria and renal failure among women with HIV infection. , 2002, Kidney international.

[74]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.